← Back to Search

Other

LY3502970 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 36
Awards & highlights

Summary

This trial is testing a new drug called LY3502970 to see if it can help people who are overweight or have obesity lose weight.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline in BMI in LY3502970 and Placebo
Change From Baseline in Body Weight in LY3502970 and Placebo
Change From Baseline in Waist Circumference in LY3502970 and Placebo
+3 more

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719
38%
Nausea
21%
Vomiting
16%
Diarrhoea
13%
Constipation
9%
Fatigue
9%
Covid-19
9%
Lipase increased
7%
Dyspepsia
7%
Gastrooesophageal reflux disease
5%
Palpitations
5%
Abdominal distension
5%
Decreased appetite
4%
Eructation
4%
Weight decreased
4%
Arthralgia
4%
Headache
4%
Urticaria
2%
Abdominal pain upper
2%
Upper respiratory tract infection
2%
Muscle spasms
2%
Dizziness
2%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 1
36 mg LY3502970 - 2
45 mg LY3502970 - 1
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: 45 mg-2 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Group II: 45 mg-1 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Group III: 36 mg-2 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Group IV: 36 mg-1 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Group V: 24 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
Group VI: 12 milligram (mg) LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
Group VII: PlaceboPlacebo Group1 Intervention
Participants received placebo administered orally once daily until 36 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1270

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,221,372 Total Patients Enrolled
60 Trials studying Obesity
52,315 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
~69 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top